Business Wire

DVB Bank’s Aviation Investment and Asset Management Business to Be Acquired by SVPGlobal and EnTrust Global

11.3.2021 15:00:00 EET | Business Wire | Press release

Share

The Blue Sky Aviation strategy managed by EnTrust Global (“EnTrust”), a leading alternative asset management firm, and funds managed by Strategic Value Partners, LLC and its affiliates ("SVPGlobal"), a global investment firm, have today announced that they have entered into a definitive agreement to acquire the Aviation Investment and Asset Management business (the “Business”) from DVB Bank Group. The transaction is expected to close during the first half of 2021.

The Business, one of the top 10 aviation service companies globally, will be acquired through a newly incorporated UK company, Deucalion Aviation Limited (“Deucalion” or the “Company”). Today, the Business is a global aviation management platform that provides comprehensive turnkey solutions for financial investors looking to deploy capital in aircraft assets, through origination, structuring, execution, fund management and a full-fledged range of servicing activities, including aircraft remarketing, technical management, lease management and consultancy. The 45-strong team manages approximately 160 aircraft on lease to more than 80 airlines globally, representing approximately $5 billion in total asset value.

EnTrust and SVPGlobal’s investment is expected to provide the support required by the existing management team to build on its international growth strategy and explore complementary opportunities arising from the current aviation industry dislocation.

Deucalion, which will be led jointly by Jon Skirrow and Stephan Sayre, will be acquired through a joint venture formed between EnTrust and SVPGlobal, utilising the two firms’ complementary expertise. Senior members of the EnTrust Blue Sky Aviation and SVPGlobal teams have worked together on various transactions over the past 15 years.

Jon Skirrow said: “We are delighted to be partnering with EnTrust and SVPGlobal, following many successful years with DVB Bank Group. This new investment will support us in capitalizing on our strong growth trajectory, and we look forward to continuing to provide our world-leading services to our clients as we embark on the next stage of our development.”

Stephan Sayre added: “EnTrust and SVPGlobal, who share our vision of the opportunities in this sector today and in the long term, enable us not only to reinforce our commitment to providing best-in-class service for our clients, but also to significantly strengthen our offering of a broad array of innovative financing solutions to airline and leasing clients globally in the current environment.”

Victor Khosla, Founder & CIO of SVPGlobal, said: “This is an innovative platform with world class aviation expertise and an excellent track record in managing complex, large and unique projects across diversified asset types and structures over the last 17 years. Our investment as part of this joint venture with EnTrust is a testament to the sizeable market opportunity set we see ahead for the business.”

John Morabito, Senior Managing Director and Portfolio Manager of EnTrust Global’s Blue Sky Aviation strategy, said: “As we continue to build a multi-faceted, relative value investment platform in the aviation industry, this acquisition enhances EnTrust’s Blue Sky Aviation strategy with the full service capabilities critical to providing a wide offering of solutions to constituents within the market. We look forward to the opportunity to partner with SVPGlobal and the talented DVB management team, with whom our team has a long-standing relationship.”

About DVB

DVB Bank SE is a financial services provider specialising in international transport finance. With 329 employees and offices worldwide, the Bank manages a loan portfolio worth €3.9 billion. As an affiliate of DZ BANK AG Deutsche Zentral-Genossenschaftsbank, Frankfurt am Main, DVB is part of Germany's second-largest banking group. Please visit our website www.dvbbank.com for additional information.

About EnTrust Global

EnTrust Global is a leading alternative asset management firm with approximately $19 billion in total assets*. Co-founded in 1997 by Chairman and CEO Gregg S. Hymowitz, the firm manages assets for over 500 institutional investors representing 47 countries and has approximately $10 billion in customized strategic partnerships. EnTrust Global offers a diverse range of alternative investment opportunities across strategies, including private debt and real assets as well as opportunistic co-investments and direct investments. EnTrust Global has 11 offices worldwide and is headquartered in New York and London.

*As of September 30, 2020. Based on estimates and includes assets under advisement and mandates awarded but not yet funded.

About Strategic Value Partners

SVPGlobal is a global investment firm with approximately $11 billion in assets under management. The firm, established by Victor Khosla in 2001, has 127 employees, including 49 investment professionals, across its main offices in Greenwich (CT), London and Tokyo. Learn more at www.svpglobal.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

DVB
Stephan Sayre
Stephan.Sayre@dvbbank.com
+44 207 2564 344

Jon Skirrow
Jon.Skirrow@dvbbank.com
+44 207 2564 430

EnTrust Global
Hiltzik Strategies
Meghan Kilkenny, Chris Cunningham
EnTrust@hstrategies.com
+1 (212) 792-9338

SVPGlobal Europe
Greenbrook Communications
James Madsen, Mikaela Murekian, Fanni Bodri
svp@greenbrookpr.com
+44 20 7952 2000

SVPGlobal – North America
Kekst CNC
Todd Fogarty, Richard Goldman
SVPGlobal@kekstcnc.com
+1 (212) 521-4800

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 12:18:00 EEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 11:11:00 EEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye